Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment

Clinical Pharmacology and Therapeutics

Volumn 101, Issue 5, 2017, Pages 634-645

  Yuraszeck, T ^a   Kasichayanula, S ^a   Benjamin, J E ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC T CELL ENGAGING ANTIBODY; BLINATUMOMAB; DEXAMETHASONE; UNCLASSIFIED DRUG; CANCER ANTIBODY; MEMBRANE ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG SAFETY; FIRST IN HUMAN STUDY; HUMAN; MALIGNANT NEOPLASM; MONOTHERAPY; OUTCOMES RESEARCH; PHARMACOKINETICS; PHARMACOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANTIBODIES, BISPECIFIC; ANTIBODIES, NEOPLASM; ANTIGENS, SURFACE; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 85018526231     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.651     Document Type: Article

References (88)

1. Khalil, D.N., Smith, E.L., Brentjens, R.J. & Wolchok, J.D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273–290 (2016).
2. Morrissey, K.M., Yuraszeck, T.M., Li, C.C., Zhang, Y. & Kasichayanula, S. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin. Transl. Sci. 9, 89–104 (2016).
3. Coley, W.B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthopaed. Relat. Res. 262, 3–11 (1991).
4. McCarthy, E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthopaed. J. 26, 154–158 (2006).
5. Ehrlich, P. Ueber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd 5, 273–290 (1909).
6. Burnet, F.M. Immunological surveillance in neoplasia. Transpl. Rev. 7, 3–25 (1971).
7. Thomas, L. On immunosurveillance in human cancer. Yale J. Biol. Med. 55, 329–333 (1982).
8. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J. & Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998 (2002).
9. Ikeda, H., Old, L.J. & Schreiber, R.D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13, 95–109 (2002).
10. Fridman, W.H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
11. Kawakami, Y. et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. U. S. A. 91, 6458–6462 (1994).
12. Schumacher, T.N. & Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
13. Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009).
14. Foley, E.J. Cancer Res. 13, 835–837 (1953).
15. Nobel prize in physiology or medicine 1972. Accessed November 11, 2015.
16. Burnet, M. Br. Med. J. 1, 779–786 (1957).
17. Fudenberg, H.H., et al. J. Exp. Med. 119, 151–166 (1964).
18. Nobel prize in physiology or medicine 1972. Accessed November 11, 2015.
19. Miller, R.A., et al. N. Engl. J. Med. 306, 517–522, (1981).
20. Chames, P., et al. mAbs. 1, 539–547 (2009).
21. Bindon, C., et al. Br. J. Cancer. 47, 123–133 (1983).
22. Bohlen, H., et al. Blood 82, 1803–1812 (1993).
23. Rosenberg, S.A., et al. N. Engl. J. Med. 319, 1676–1680 (1988).
24. van der Bruggen, P., et al. Science 254, 1643–1647 (1991).
25. Mack, M., et al. Proc. Natl. Acad. Sci. U. S. A. 92, 7021–7025 (1995).
26. Frankel, S.R., et al. Curr. Opin. Chem. Biol. 17, 385–392 (2013).
27. Linke, R., et al. mAbs. 2, 129–136 (2010).
28. Chen, D.S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
29. Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P. & Baeuerle, P.A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 43, 763–771 (2006).
30. Deisting, W., Raum, T., Kufer, P., Baeuerle, P.A. & Münz, M. Impact of diverse immune evasion mechanisms of cancer cells on T cells engaged by EpCAM/CD3-bispecific antibody construct AMG 110. PLoS One 10, e0141669 (2015).
31. Przepiorka, D. et al. FDA approval: blinatumomab. Clin. Cancer Res. 21, 4035–4039 (2015).
32. Dreier, T. et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J. Immunol. 170, 4397–4402 (2003).
33. Schlereth, B. et al. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunol. Immunother. 55, 785–796 (2006).
34. Raponi, S. et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leukemia Lymphoma 52, 1098–1107 (2011).
35. Wang, K., Wei, G. & Liu, D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp. Hematol. Oncol. 1, 36 (2012).
36. Dreier, T. et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer 100, 690–697 (2002).
37. Brischwein, K. et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE® class. J. Immunother. 30, 798–807 (2007).
38. Loffler, A. et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098–2103 (2000).
39. Hoffmann, P. et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer 115, 98–104 (2005).
40. Benjamin, J.E. & Stein, A.S. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther. Adv. Hematol. 7, 142–156 (2016).
41. Friedrich, M. et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol. Cancer Ther. 13, 1549–1557 (2014).
42. Brischwein, K. et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol. Immunol. 43, 1129–1143 (2006).
43. Warnders, F.J. et al. Biodistribution and PET imaging of labeled bispecific T cell-engaging antibody targeting EpCAM. J. Nucl. Med. 57, 812–817 (2016).
44. Pui, C.H. & Jeha, S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat. Rev. Drug Disc. 6, 149–165 (2007).
45. Lin, K.-T. & Wang, L.-H. New dimension of glucocorticoids in cancer treatment. Steroids 111, 84–88 (2016).
46. Brandl, C. et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol. Immunother. 56, 1551–1563 (2007).
47. Fiedler, W.M. et al. Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE® antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer. J. Clin. Oncol. 28, 2573–2573 (2010).
48. Pishvaian, M. et al. Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas. Clin. Colorectal Cancer 15, 345–351 (2016).
49. Eastwood, D. et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 161, 512–526 (2010).
50. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on Strategies to Identify and Mitigate Risks for First-in–Human Clinical Trials with Investigational Medicinal Products (July 2007).
51. Nagorsen, D., Kufer, P., Baeuerle, P.A. & Bargou, R. Blinatumomab: a historical perspective. Pharmacol. Ther. 136, 334–342 (2012).
52. Stone, M.J. et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88, 1188–1197 (1996).
53. Davila, M.L. et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med.e 6, 224ra225 (2014).
54. Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974–977 (2008).
55. Goebeler, M.E. et al. Bispecific T-cell engager (BiTE®) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J. Clin. Oncol. 34, 1104–1111 (2016).
56. Zhu, M. et al. Blinatumomab, a bispecific T-cell engager (BiTE®((R))) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin. Pharmacokinet. 55, 1271–1288 (2016).
57. Pettengell, R. et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 13, 696–706 (2012).
58. Wang, M. et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27, 1902–1909 (2013).
59. Viardot, A. et al. Phase 2 study of the bispecific T-cell engager (BiTE®) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 127, 1410–1416 (2016).
60. Dores, G.M., Devesa, S.S., Curtis, R.E., Linet, M.S. & Morton, L.M. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 119, 34–43 (2012).
61. Pui, C.H. et al. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia, 28, 2336–2343 (2014).
62. Hoelzer, D. et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87, 495–508 (1996).
63. Larson, R.A. et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85, 2025–2037 (1995).
64. Gokbuget, N. et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 101, 1524–1533 (2016).
65. Coustan-Smith, E. et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96, 2691–2696 (2000).
66. Bruggemann, M. et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107, 1116–1123 (2006).
67. Gokbuget, N. et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120, 2032–2041 (2012).
68. Thomas, D.A. et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 86, 1216–1230 (1999).
69. Fielding, A.K. et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109, 944–950 (2007).
70. Topp, M.S. et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32, 4134–4140 (2014).
71. Topp, M.S. et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493–2498 (2011).
72. Topp, M.S. et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120, 5185–5187 (2012).
73. Goekbuget, N. et al. An evaluation of molecular response in a phase 2 open-label, multicenter confirmatory study in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) receiving treatment with the BiTE® antibody construct blinatumomab. Blood 124, 3704–3704 (2014).
74. Topp, M.S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16, 57–66 (2015).
75. Topp, M.S., Gockbuget, N. & Stein, A.S. Correction to Lancet Oncol 2015; 16: 60, 61. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 study. Lancet Oncol. 16, e158 (2015).
76. Topp, M.S. et al. Blinatumomab improved overall survival in patients with relapsed or refractory philadelphia negative b-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (Tower). European Hematology Association. Copenhagen, Denmark (June 10, 2016).
77. von Stackelberg, A. et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 34, 4381–4389 (2016).
78. Wu, B. & Sun, Y.N. Pharmacokinetics of Peptide-Fc fusion proteins. J. Pharm. Sci. 103, 53–64 (2014).
79. Kenny, J.R. et al. Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop. AAPS J 15, 933–940 (2013).
80. Xu, Y. et al. Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity. CPT Pharmacometrics Syst. Pharmacol. 4, 507–515 (2015).
81. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing and Labeling (March 2010).
82. Singh, I. et al. A systems pharmacology model to characterize the effect of blinatumomab in patients with adult B precursor acute lymphoblastic leukemia. Poster presented at the ASCPT annual meeting, Atlanta, GA (March 2014).
83. Yuraszeck, T. et al. A population-based approach to systems pharmacology modeling of the effect of blinatumomab (blin) in adult B-precursor ALL patients. Poster presented at the ASCPT annual meeting, San Diego, CA (March 2016).
84. Kohnke, T., Krupka, C., Tischer, J., Knosel, T. & Subklewe, M. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J. Hematol. Oncol. 8, 111 (2015).
85. Feucht, J. et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE®) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 7, 76902–76919 (2016).
86. Klinger, M. et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE® antibody blinatumomab. Blood 119, 6226–6233 (2012).
87. Goekbuget, N. et al. BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Blood 124, 379–379 (2014).
88. Gökbuget, N. et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). Blood 126, 680–680 (2015).